NASDAQ:OTLK

Outlook Therapeutics Competitors

$1.81
-0.02 (-1.09 %)
(As of 04/20/2021 11:21 AM ET)
Add
Compare
Today's Range
$1.80
Now: $1.81
$1.94
50-Day Range
$1.81
MA: $2.15
$2.48
52-Week Range
$0.58
Now: $1.81
$4.26
Volume21,414 shs
Average Volume4.26 million shs
Market Capitalization$314.23 million
P/E RatioN/A
Dividend YieldN/A
Beta0.46

Competitors

Outlook Therapeutics (NASDAQ:OTLK) Vs. FMTX, MESO, ATRA, CRTX, SRRK, and OCGN

Should you be buying OTLK stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Outlook Therapeutics, including Forma Therapeutics (FMTX), Mesoblast (MESO), Atara Biotherapeutics (ATRA), Cortexyme (CRTX), Scholar Rock (SRRK), and Ocugen (OCGN).

Outlook Therapeutics (NASDAQ:OTLK) and Forma Therapeutics (NASDAQ:FMTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends and profitability.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Outlook Therapeutics and Forma Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Outlook Therapeutics00403.00
Forma Therapeutics00603.00

Outlook Therapeutics presently has a consensus price target of $6.3333, suggesting a potential upside of 229.86%. Forma Therapeutics has a consensus price target of $61.6667, suggesting a potential upside of 147.46%. Given Outlook Therapeutics' higher probable upside, equities research analysts plainly believe Outlook Therapeutics is more favorable than Forma Therapeutics.

Profitability

This table compares Outlook Therapeutics and Forma Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Outlook TherapeuticsN/AN/A-148.04%
Forma TherapeuticsN/A-29.54%-20.61%

Insider & Institutional Ownership

3.0% of Outlook Therapeutics shares are owned by institutional investors. Comparatively, 67.3% of Forma Therapeutics shares are owned by institutional investors. 4.0% of Outlook Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Outlook Therapeutics and Forma Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Outlook Therapeutics$8.15 million38.56$-35,240,000.00($0.67)-2.70
Forma Therapeutics$100.56 million11.82$-34,790,000.00N/AN/A

Forma Therapeutics has higher revenue and earnings than Outlook Therapeutics.

Summary

Forma Therapeutics beats Outlook Therapeutics on 5 of the 9 factors compared between the two stocks.

Outlook Therapeutics (NASDAQ:OTLK) and Mesoblast (NASDAQ:MESO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Profitability

This table compares Outlook Therapeutics and Mesoblast's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Outlook TherapeuticsN/AN/A-148.04%
Mesoblast-591.00%-18.69%-13.85%

Analyst Ratings

This is a summary of recent ratings for Outlook Therapeutics and Mesoblast, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Outlook Therapeutics00403.00
Mesoblast12302.33

Outlook Therapeutics currently has a consensus target price of $6.3333, suggesting a potential upside of 229.86%. Mesoblast has a consensus target price of $14.55, suggesting a potential upside of 65.15%. Given Outlook Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Outlook Therapeutics is more favorable than Mesoblast.

Risk and Volatility

Outlook Therapeutics has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500. Comparatively, Mesoblast has a beta of 3.71, suggesting that its share price is 271% more volatile than the S&P 500.

Institutional and Insider Ownership

3.0% of Outlook Therapeutics shares are owned by institutional investors. Comparatively, 2.8% of Mesoblast shares are owned by institutional investors. 4.0% of Outlook Therapeutics shares are owned by company insiders. Comparatively, 18.8% of Mesoblast shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Outlook Therapeutics and Mesoblast's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Outlook Therapeutics$8.15 million38.56$-35,240,000.00($0.67)-2.70
Mesoblast$32.16 million35.14$-77,940,000.00($0.74)-11.77

Outlook Therapeutics has higher earnings, but lower revenue than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Outlook Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Outlook Therapeutics beats Mesoblast on 10 of the 14 factors compared between the two stocks.

Atara Biotherapeutics (NASDAQ:ATRA) and Outlook Therapeutics (NASDAQ:OTLK) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, risk and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings and target prices for Atara Biotherapeutics and Outlook Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atara Biotherapeutics03702.70
Outlook Therapeutics00403.00

Atara Biotherapeutics presently has a consensus price target of $35.8750, suggesting a potential upside of 167.92%. Outlook Therapeutics has a consensus price target of $6.3333, suggesting a potential upside of 229.86%. Given Outlook Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Outlook Therapeutics is more favorable than Atara Biotherapeutics.

Volatility & Risk

Atara Biotherapeutics has a beta of 2.65, indicating that its stock price is 165% more volatile than the S&P 500. Comparatively, Outlook Therapeutics has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500.

Valuation and Earnings

This table compares Atara Biotherapeutics and Outlook Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atara BiotherapeuticsN/AN/A$-290,980,000.00($5.67)-2.30
Outlook Therapeutics$8.15 million38.56$-35,240,000.00($0.67)-2.70

Outlook Therapeutics has higher revenue and earnings than Atara Biotherapeutics. Outlook Therapeutics is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Atara Biotherapeutics and Outlook Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Atara BiotherapeuticsN/A-94.86%-82.17%
Outlook TherapeuticsN/AN/A-148.04%

Institutional & Insider Ownership

3.0% of Outlook Therapeutics shares are held by institutional investors. 4.3% of Atara Biotherapeutics shares are held by company insiders. Comparatively, 4.0% of Outlook Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Outlook Therapeutics beats Atara Biotherapeutics on 8 of the 12 factors compared between the two stocks.

Cortexyme (NASDAQ:CRTX) and Outlook Therapeutics (NASDAQ:OTLK) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, profitability, valuation and earnings.

Institutional and Insider Ownership

55.5% of Cortexyme shares are owned by institutional investors. Comparatively, 3.0% of Outlook Therapeutics shares are owned by institutional investors. 19.8% of Cortexyme shares are owned by insiders. Comparatively, 4.0% of Outlook Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Cortexyme has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Outlook Therapeutics has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Cortexyme and Outlook Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cortexyme21402.29
Outlook Therapeutics00403.00

Cortexyme presently has a consensus price target of $50.00, suggesting a potential upside of 32.14%. Outlook Therapeutics has a consensus price target of $6.3333, suggesting a potential upside of 229.86%. Given Outlook Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Outlook Therapeutics is more favorable than Cortexyme.

Profitability

This table compares Cortexyme and Outlook Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CortexymeN/A-37.78%-35.24%
Outlook TherapeuticsN/AN/A-148.04%

Earnings and Valuation

This table compares Cortexyme and Outlook Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CortexymeN/AN/A$-36,980,000.00($1.94)-19.40
Outlook Therapeutics$8.15 million38.56$-35,240,000.00($0.67)-2.70

Outlook Therapeutics has higher revenue and earnings than Cortexyme. Cortexyme is trading at a lower price-to-earnings ratio than Outlook Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Outlook Therapeutics beats Cortexyme on 7 of the 11 factors compared between the two stocks.

Scholar Rock (NASDAQ:SRRK) and Outlook Therapeutics (NASDAQ:OTLK) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Scholar Rock and Outlook Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Scholar Rock00503.00
Outlook Therapeutics00403.00

Scholar Rock currently has a consensus price target of $61.60, suggesting a potential upside of 92.86%. Outlook Therapeutics has a consensus price target of $6.3333, suggesting a potential upside of 229.86%. Given Outlook Therapeutics' higher possible upside, analysts plainly believe Outlook Therapeutics is more favorable than Scholar Rock.

Institutional and Insider Ownership

61.9% of Scholar Rock shares are held by institutional investors. Comparatively, 3.0% of Outlook Therapeutics shares are held by institutional investors. 24.6% of Scholar Rock shares are held by company insiders. Comparatively, 4.0% of Outlook Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Scholar Rock has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500. Comparatively, Outlook Therapeutics has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500.

Earnings and Valuation

This table compares Scholar Rock and Outlook Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scholar Rock$20.49 million52.22$-51,000,000.00($1.85)-16.88
Outlook Therapeutics$8.15 million38.56$-35,240,000.00($0.67)-2.70

Outlook Therapeutics has lower revenue, but higher earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Outlook Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Scholar Rock and Outlook Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Scholar Rock-365.84%-80.16%-41.33%
Outlook TherapeuticsN/AN/A-148.04%

Summary

Outlook Therapeutics beats Scholar Rock on 7 of the 13 factors compared between the two stocks.

Ocugen (NASDAQ:OCGN) and Outlook Therapeutics (NASDAQ:OTLK) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, earnings and profitability.

Analyst Recommendations

This is a breakdown of recent ratings for Ocugen and Outlook Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ocugen01302.75
Outlook Therapeutics00403.00

Ocugen currently has a consensus target price of $4.80, indicating a potential downside of 12.73%. Outlook Therapeutics has a consensus target price of $6.3333, indicating a potential upside of 229.86%. Given Outlook Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Outlook Therapeutics is more favorable than Ocugen.

Institutional & Insider Ownership

8.5% of Ocugen shares are held by institutional investors. Comparatively, 3.0% of Outlook Therapeutics shares are held by institutional investors. 3.5% of Ocugen shares are held by insiders. Comparatively, 4.0% of Outlook Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Ocugen has a beta of 3.56, suggesting that its stock price is 256% more volatile than the S&P 500. Comparatively, Outlook Therapeutics has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500.

Valuation & Earnings

This table compares Ocugen and Outlook Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OcugenN/AN/A$-20,240,000.00($1.48)-3.55
Outlook Therapeutics$8.15 million38.56$-35,240,000.00($0.67)-2.70

Ocugen has higher earnings, but lower revenue than Outlook Therapeutics. Ocugen is trading at a lower price-to-earnings ratio than Outlook Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ocugen and Outlook Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OcugenN/A-47.72%-30.78%
Outlook TherapeuticsN/AN/A-148.04%

Summary

Outlook Therapeutics beats Ocugen on 8 of the 12 factors compared between the two stocks.


Outlook Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.8$25.09-0.5%$1.18 billion$100.56 million0.00Increase in Short Interest
Mesoblast logo
MESO
Mesoblast
1.4$8.71-1.1%$1.14 billion$32.16 million-9.90Decrease in Short Interest
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$13.04-2.0%$1.11 billionN/A-2.82
Cortexyme logo
CRTX
Cortexyme
1.3$37.64-2.4%$1.09 billionN/A-15.68
Scholar Rock logo
SRRK
Scholar Rock
1.5$31.23-0.4%$1.07 billion$20.49 million-12.96Increase in Short Interest
Ocugen logo
OCGN
Ocugen
1.1$5.26-7.2%$1.06 billionN/A-3.55Gap Down
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$14.17-0.2%$1.03 billion$356.07 million6.95
Curis logo
CRIS
Curis
1.3$9.87-4.5%$943.56 million$10 million-12.04News Coverage
Vaxcyte logo
PCVX
Vaxcyte
1.7$17.71-0.7%$903.33 millionN/A0.00Increase in Short Interest
News Coverage
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.6$22.52-2.9%$884.02 millionN/A-9.31Increase in Short Interest
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.5$8.80-1.8%$876.25 million$250,000.00-6.93
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$22.97-5.2%$873.09 millionN/A-3.80Increase in Short Interest
Gap Up
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$22.89-0.5%$868.88 millionN/A0.00Analyst Report
Gap Up
Passage Bio logo
PASG
Passage Bio
1.8$16.02-0.3%$867.41 millionN/A0.00
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$18.11-3.1%$857.26 million$42.74 million-201.22Analyst Revision
Gap Up
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.93-1.8%$821.60 millionN/A0.00Gap Down
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$17.15-1.4%$815.89 million$69.89 million-4.09
Cellectis logo
CLLS
Cellectis
1.3$18.00-3.6%$797.85 million$22.99 million-9.57
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$5.71-3.5%$731.04 million$2.51 million-3.46
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.5$4.69-0.2%$727.59 million$1.12 million-4.74
Inhibrx logo
INBX
Inhibrx
1.6$17.78-3.9%$697.58 millionN/A0.00Decrease in Short Interest
DBV Technologies logo
DBVT
DBV Technologies
1.0$5.90-1.4%$657.04 million$14.75 million-2.53Increase in Short Interest
Harpoon Therapeutics logo
HARP
Harpoon Therapeutics
1.5$18.47-3.7%$621.00 million$5.78 million-8.67Increase in Short Interest
Athira Pharma logo
ATHA
Athira Pharma
2.1$16.64-0.1%$618.05 millionN/A0.00Gap Up
Vaxart logo
VXRT
Vaxart
1.3$4.93-3.7%$601.79 million$9.86 million-8.36
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.27-0.5%$590.04 million$13.29 million-9.41News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.5$27.90-2.5%$570.80 millionN/A0.00
Compugen logo
CGEN
Compugen
1.4$8.03-3.2%$567.20 million$17.80 million-21.70News Coverage
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.8$8.45-1.5%$532.89 millionN/A-1.23
Solid Biosciences logo
SLDB
Solid Biosciences
1.8$4.79-2.5%$524.77 millionN/A-2.33
Agenus logo
AGEN
Agenus
1.6$2.53-1.2%$523.99 million$150.05 million-2.32
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.0$19.12-4.1%$515.87 millionN/A-5.51
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$8.17-0.5%$464.56 million$22.24 million-4.06
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$4.78-6.1%$450.42 millionN/A-7.47
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
1.6$12.25-1.4%$439.22 millionN/A0.00
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$8.41-4.4%$429.80 million$4.36 million-2.94
AVROBIO logo
AVRO
AVROBIO
1.7$10.20-0.6%$427.04 millionN/A-3.09Analyst Downgrade
News Coverage
Opthea logo
OPT
Opthea
1.5$8.96-1.6%$389.38 millionN/A0.00
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.6$8.55-0.5%$386.30 million$147.87 million-2.84
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$8.68-2.8%$363.22 millionN/A0.00
SQZ Biotechnologies logo
SQZ
SQZ Biotechnologies
1.7$11.95-4.7%$348.65 millionN/A0.00
Innate Pharma logo
IPHA
Innate Pharma
1.1$4.13-2.2%$333.34 million$96.12 million-12.15News Coverage
Gap Up
Cardiff Oncology logo
CRDF
Cardiff Oncology
2.0$8.00-0.8%$302.67 million$250,000.00-2.86
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.3$5.20-1.5%$276.39 million$2.91 million-1.81News Coverage
Surface Oncology logo
SURF
Surface Oncology
1.4$6.33-3.6%$273.74 million$15.36 million-9.59
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.8$7.93-1.3%$272.23 millionN/A-3.26
Cabaletta Bio logo
CABA
Cabaletta Bio
1.6$10.81-0.6%$258.68 millionN/A-7.89
Codiak BioSciences logo
CDAK
Codiak BioSciences
2.0$11.55-1.7%$258.43 millionN/A0.00
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.7$1.64-3.7%$237.66 million$4.13 million-3.64
ADMA Biologics logo
ADMA
ADMA Biologics
1.6$1.55-6.1%$198.89 million$29.35 million-1.80
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.